Ashwagandha

Adaptogenic herb with withanolides inducing apoptosis, inhibiting NF-κB; reduces chemo fatigue in one human study.

AI extractedhuman reviewedsources checkedretractions suppressed

🔬⭐⭐ Moderate — Strong preclinical data plus one supportive human trial for symptom management.Withania somniferaIndian ginsengWinter cherry

Forms: Root extract standardized to 5% withanolides · Whole root powder/capsules · Withaferin A-enriched extract (research use)

Educational only, not medical advice. OncoForge makes no claim that Ashwagandha treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.

Simple Summary

Ashwagandha is an adaptogenic herb that may help reduce fatigue from chemotherapy and has shown promise in lab studies for killing cancer cells and curbing inflammation. One study in breast cancer patients found it improved quality of life during treatment.

Evidence at a glance

Tier 2 · animalBreast cancer (supportive)Lung, colon, prostate (preclinical)

Robust preclinical anticancer mechanisms; limited human data focused on supportive care (fatigue reduction) in breast cancer.

How it may work

Ashwagandha (Withania somnifera) and its key compound withaferin A induce apoptosis in cancer cells via ROS generation, mitochondrial disruption, and p53 activation. It inhibits NF-κB signaling, reducing inflammation and angiogenesis. Preclinical data show cytotoxicity against breast, lung, colon, and other cancers, with immunomodulatory effects enhancing T-cell activity. In humans, it may alleviate chemotherapy-induced fatigue.

Targets & pathways

Curated mechanistic targets reported for this agent — how it may act on cells, not proof of a clinical effect.

Apoptosis (cancer cells)↑ROS-mediated; p53-dependent
NF-κB↓Reduces proinflammatory cytokines (IL-6, TNF-α)
Angiogenesis↓VEGF inhibition (preclinical)
T-cell activity↑Immunomodulation
Chemotherapy fatigue↓Human trial evidence
Tumor growth↓In vitro/in vivo models (breast, lung, colon)

Anti-inflammatoryApoptosis Induction

Often studied / combined with

Combinations reported in the literature, not a protocol or a recommendation.

Chemotherapy: Reduces fatigue and improves QoL in human study; potential radiosensitization preclinical.
Curcumin: Complementary anti-inflammatory and NF-κB inhibition.

Overlapping mechanisms

Anti-inflammatory ↓, Apoptosis ↑: Monitor for additive liver effects with other herbals.

Safety & interactions

Severity and how well-established each signal is are shown separately. Verify everything with your oncologist or pharmacist — absence here does not mean safe.

Risk categories

Liver Enzyme Elevation RiskHormone Sensitive CautionSedative EffectsPregnancy AvoidThyroid Interference Risk

Potential interactions

sedatives (benzodiazepines, barbiturates)MonitorModerateTheoreticalAdditive CNS depression; increased drowsiness.
chemotherapy (general)MonitorTheoreticalSupportive for fatigue; no known antagonism, but coordinate with oncologist.
thyroid medicationsDose AdjustMildTheoreticalMay enhance thyroid function; monitor levels.
immunosuppressantsAvoidModerateTheoreticalImmunostimulatory effects may counteract.

Timing

With-meal: Reduces GI upset.
PM: Adaptogenic effects may aid sleep.

References

Research

No published studies for Ashwagandha yet

New studies appear here once they’ve been reviewed. Browse all studies.

Dose: as studied, not a recommendation

These are doses as studied or reported, never a recommendation. The right amount of Ashwagandha depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.

Ranges seen in adjunct / practice use: 2–6 g (oral) 2 g TID of root extract; with meals to improve tolerance, Based on breast cancer fatigue trial (PMID 23142798); adjust for standardized withanolide content (typically 2.5-5%)..

Trials studying Ashwagandha

1 recruiting on ClinicalTrials.gov. Recruiting is not the same as proven. Search ClinicalTrials.gov →

Combination Therapy for Recurrent Ovarian Cancer
NCT05610735Phase 1 / Phase 2Recruiting

Trials studying Ashwagandha

Loading current trials from ClinicalTrials.gov… Search ClinicalTrials.gov →

Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.

← All agents · Research Radar